The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation.

Fruchart JC, Santos RD, Aguilar-Salinas C, Aikawa M, Al Rasadi K, Amarenco P, Barter PJ, Ceska R, Corsini A, Després JP, Duriez P, Eckel RH, Ezhov MV, Farnier M, Ginsberg HN, Hermans MP, Ishibashi S, Karpe F, Kodama T, Koenig W, Krempf M, Lim S, Lorenzatti AJ, McPherson R, Nuñez-Cortes JM, Nordestgaard BG, Ogawa H, Packard CJ, Plutzky J, Ponte-Negretti CI, Pradhan A, Ray KK, Reiner Ž, Ridker PM, Ruscica M, Sadikot S, Shimano H, Sritara P, Stock JK, Su TC, Susekov AV, Tartar A, Taskinen MR, Tenenbaum A, Tokgözoğlu LS, Tomlinson B, Tybjærg-Hansen A, Valensi P, Vrablík M, Wahli W, Watts GF, Yamashita S, Yokote K, Zambon A, Libby P

Open source

DOI: 10.1186/s12933-019-0864-7
Published: 2019 Jun 4
Container: Cardiovascular diabetology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1186/s12933-019-0864-7,
  title = {The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation.},
  author = {Fruchart JC and Santos RD and Aguilar-Salinas C and Aikawa M and Al Rasadi K and Amarenco P and Barter PJ and Ceska R and Corsini A and Després JP and Duriez P and Eckel RH and Ezhov MV and Farnier M and Ginsberg HN and Hermans MP and Ishibashi S and Karpe F and Kodama T and Koenig W and Krempf M and Lim S and Lorenzatti AJ and McPherson R and Nuñez-Cortes JM and Nordestgaard BG and Ogawa H and Packard CJ and Plutzky J and Ponte-Negretti CI and Pradhan A and Ray KK and Reiner Ž and Ridker PM and Ruscica M and Sadikot S and Shimano H and Sritara P and Stock JK and Su TC and Susekov AV and Tartar A and Taskinen MR and Tenenbaum A and Tokgözoğlu LS and Tomlinson B and Tybjærg-Hansen A and Valensi P and Vrablík M and Wahli W and Watts GF and Yamashita S and Yokote K and Zambon A and Libby P},
  year = {2019},
  journal = {Cardiovascular diabetology},
  doi = {10.1186/s12933-019-0864-7},
  url = {https://doi.org/10.1186/s12933-019-0864-7}
}

RIS

TY  - JOUR
TI  - The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation.
AU  - Fruchart JC
AU  - Santos RD
AU  - Aguilar-Salinas C
AU  - Aikawa M
AU  - Al Rasadi K
AU  - Amarenco P
AU  - Barter PJ
AU  - Ceska R
AU  - Corsini A
AU  - Després JP
AU  - Duriez P
AU  - Eckel RH
AU  - Ezhov MV
AU  - Farnier M
AU  - Ginsberg HN
AU  - Hermans MP
AU  - Ishibashi S
AU  - Karpe F
AU  - Kodama T
AU  - Koenig W
AU  - Krempf M
AU  - Lim S
AU  - Lorenzatti AJ
AU  - McPherson R
AU  - Nuñez-Cortes JM
AU  - Nordestgaard BG
AU  - Ogawa H
AU  - Packard CJ
AU  - Plutzky J
AU  - Ponte-Negretti CI
AU  - Pradhan A
AU  - Ray KK
AU  - Reiner Ž
AU  - Ridker PM
AU  - Ruscica M
AU  - Sadikot S
AU  - Shimano H
AU  - Sritara P
AU  - Stock JK
AU  - Su TC
AU  - Susekov AV
AU  - Tartar A
AU  - Taskinen MR
AU  - Tenenbaum A
AU  - Tokgözoğlu LS
AU  - Tomlinson B
AU  - Tybjærg-Hansen A
AU  - Valensi P
AU  - Vrablík M
AU  - Wahli W
AU  - Watts GF
AU  - Yamashita S
AU  - Yokote K
AU  - Zambon A
AU  - Libby P
PY  - 2019
JO  - Cardiovascular diabetology
DO  - 10.1186/s12933-019-0864-7
UR  - https://doi.org/10.1186/s12933-019-0864-7
ER  -

APA

JC, F., RD, S., C, A., M, A., K, A. R., P, A., PJ, B., R, C., A, C., JP, D., P, D., RH, E., MV, E., M, F., HN, G., MP, H., S, I., F, K., T, K., W, K., M, K., S, L., AJ, L., R, M., JM, N., BG, N., H, O., CJ, P., J, P., CI, P., A, P., KK, R., Ž, R., PM, R., M, R., S, S., H, S., P, S., JK, S., TC, S., AV, S., A, T., MR, T., A, T., LS, T., B, T., A, T., P, V., M, V., W, W., GF, W., S, Y., K, Y., A, Z., & P, L. (2019). The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation.. Cardiovascular diabetology. https://doi.org/10.1186/s12933-019-0864-7

Source records

pubmed · retrieved 2026-09-26T13:53:14.923Z